EMA probe finds no causal link be­tween semaglu­tide and sui­ci­dal thoughts, self-harm

The Eu­ro­pean Med­i­cines Agency found no link be­tween semaglu­tide use and sui­ci­dal thoughts or ac­tions, con­clud­ing a month­s­long probe that fol­lowed an in­quiry by the FDA that led to a sim­i­lar con­clu­sion last year.

The EMA’s Phar­ma­covig­i­lance Risk As­sess­ment Com­mit­tee (PRAC) be­gan look­ing last Ju­ly in­to re­ports of pa­tients tak­ing GLP-1s ex­pe­ri­enc­ing sui­ci­dal thoughts. Af­ter ex­am­in­ing sev­er­al stud­ies based on pa­tient health records, the group con­clud­ed that there was no need for the man­u­fac­tur­ers to take ac­tion on their safe­ty la­bel­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER